While Sun et al. showed, as well, that PCSK9 inhibitors are strongly associated with a lower risk of prostate cancer [84], another cohort study did not find any correlation between PCSK9 expression and a high Gleason grade or a progression to lethal cancer [85]. The gene discussed is PCSK9; the disease is prostate cancer.